-- Evaxion Biotech (EVAX) said late Friday new data demonstrates its AI-Immunology platform's ability to potentially develop vaccines for glioblastoma, a type of brain cancer.
The data will be presented at the AACR Annual Meeting in San Diego on Wednesday. This data confirms how AI-Immunology can be applied across different cancers and diseases, the company said.
Evaxion said it has collaborated with Duke University School of Medicine to identify endogenous retrovirus-derived antigens in tumor samples from several glioblastoma patients to include in vaccines targeting the brain cancer, for which a few therapeutic options are available.
The company said it also identified neoantigens of sufficient quality to include in a vaccine in most of the patients.
Price: $4.61, Change: $+0.47, Percent Change: +11.26%